Literature DB >> 26706850

Two heterozygous Cav3.2 channel mutations in a pediatric chronic pain patient: recording condition-dependent biophysical effects.

Ivana A Souza1, Maria A Gandini1, Miranda M Wan1, Gerald W Zamponi2.   

Abstract

We report expression system-dependent effects of heterozygous mutations (P769L and A1059S) in the Cav3.2 CACNA1H gene identified in a pediatric patient with chronic pain and absence seizures. The mutations were introduced individually into recombinant channels and then analyzed by means of electrophysiology. When both mutants were co-expressed in tsA-201 cells, we observed a loss of channel function, with significantly smaller current densities across a wide range of voltages (-40 to +20 mV). In addition, when both mutant channels were co-expressed, the channels opened at a more depolarizing potential with a ~5-mV right shift in the half-activation potential, with no changes in half-inactivation potential and the rate of recovery from inactivation. Interestingly, when both mutants were co-expressed in the neuronal-derived CAD cells in a different extracellular milieu, the effect was remarkably different. Although not statistically significant (p < 0.07), current densities appeared augmented compared to wild-type channels and the difference in the half-activation potential was lost. This could be attributed to the replacement of extracellular sodium and potassium with tetraethylammonium chloride. Our results show that experimental conditions can be a confounding factor in the biophysical effects of T-type calcium channel mutations found in certain neurological disorders.

Entities:  

Keywords:  Calcium channel; Epilepsy; HEK cells; Mutation; Pain; T-type

Mesh:

Substances:

Year:  2015        PMID: 26706850     DOI: 10.1007/s00424-015-1776-3

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  33 in total

1.  Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception.

Authors:  Emmanuel Bourinet; Abdelkrim Alloui; Arnaud Monteil; Christian Barrère; Brigitte Couette; Olivier Poirot; Anne Pages; John McRory; Terrance P Snutch; Alain Eschalier; Joël Nargeot
Journal:  EMBO J       Date:  2004-12-16       Impact factor: 11.598

Review 2.  Regulation of neuronal T-type calcium channels.

Authors:  Mircea C Iftinca; Gerald W Zamponi
Journal:  Trends Pharmacol Sci       Date:  2008-11-29       Impact factor: 14.819

3.  Diabetic neuropathy enhances voltage-activated Ca2+ channel activity and its control by M4 muscarinic receptors in primary sensory neurons.

Authors:  Xue-Hong Cao; Hee Sun Byun; Shao-Rui Chen; Hui-Lin Pan
Journal:  J Neurochem       Date:  2011-09-21       Impact factor: 5.372

Review 4.  Infectious mononucleosis.

Authors:  Paul Lennon; Michael Crotty; John E Fenton
Journal:  BMJ       Date:  2015-04-21

Review 5.  T-type calcium channels in burst-firing, network synchrony, and epilepsy.

Authors:  Stuart M Cain; Terrance P Snutch
Journal:  Biochim Biophys Acta       Date:  2012-08-02

6.  Gating effects of mutations in the Cav3.2 T-type calcium channel associated with childhood absence epilepsy.

Authors:  Houman Khosravani; Christophe Altier; Brett Simms; Kevin S Hamming; Terrance P Snutch; Janette Mezeyova; John E McRory; Gerald W Zamponi
Journal:  J Biol Chem       Date:  2004-01-16       Impact factor: 5.157

7.  A novel T-type current underlies prolonged Ca(2+)-dependent burst firing in GABAergic neurons of rat thalamic reticular nucleus.

Authors:  J R Huguenard; D A Prince
Journal:  J Neurosci       Date:  1992-10       Impact factor: 6.167

Review 8.  A polygenic heterogeneity model for common epilepsies with complex genetics.

Authors:  L M Dibbens; S E Heron; J C Mulley
Journal:  Genes Brain Behav       Date:  2007-06-07       Impact factor: 3.449

9.  Surface expression and function of Cav3.2 T-type calcium channels are controlled by asparagine-linked glycosylation.

Authors:  Norbert Weiss; Stefanie A G Black; Chris Bladen; Lina Chen; Gerald W Zamponi
Journal:  Pflugers Arch       Date:  2013-03-16       Impact factor: 3.657

10.  Functional analysis of Ca3.2 T-type calcium channel mutations linked to childhood absence epilepsy.

Authors:  Jean B Peloquin; Houman Khosravani; Wendy Barr; Chris Bladen; Rhian Evans; Janette Mezeyova; David Parker; Terrance P Snutch; John E McRory; Gerald W Zamponi
Journal:  Epilepsia       Date:  2006-03       Impact factor: 5.864

View more
  12 in total

1.  CACNA1H missense mutations associated with amyotrophic lateral sclerosis alter Cav3.2 T-type calcium channel activity and reticular thalamic neuron firing.

Authors:  Yuriy Rzhepetskyy; Joanna Lazniewska; Iulia Blesneac; Roger Pamphlett; Norbert Weiss
Journal:  Channels (Austin)       Date:  2016-06-22       Impact factor: 2.581

2.  CACNA1H Mutations Are Associated With Different Forms of Primary Aldosteronism.

Authors:  Georgios Daniil; Fabio L Fernandes-Rosa; Jean Chemin; Iulia Blesneac; Jacques Beltrand; Michel Polak; Xavier Jeunemaitre; Sheerazed Boulkroun; Laurence Amar; Tim M Strom; Philippe Lory; Maria-Christina Zennaro
Journal:  EBioMedicine       Date:  2016-10-04       Impact factor: 8.143

Review 3.  Neuronal Cav3 channelopathies: recent progress and perspectives.

Authors:  Philippe Lory; Sophie Nicole; Arnaud Monteil
Journal:  Pflugers Arch       Date:  2020-07-07       Impact factor: 3.657

4.  Compound heterozygous CACNA1H mutations associated with severe congenital amyotrophy.

Authors:  Melissa T Carter; Hugh J McMillan; Andriy Tomin; Norbert Weiss
Journal:  Channels (Austin)       Date:  2019-12       Impact factor: 2.581

Review 5.  Genetic T-type calcium channelopathies.

Authors:  Norbert Weiss; Gerald W Zamponi
Journal:  J Med Genet       Date:  2019-06-19       Impact factor: 6.318

6.  The de novo CACNA1A pathogenic variant Y1384C associated with hemiplegic migraine, early onset cerebellar atrophy and developmental delay leads to a loss of Cav2.1 channel function.

Authors:  Maria A Gandini; Ivana A Souza; Laurent Ferron; A Micheil Innes; Gerald W Zamponi
Journal:  Mol Brain       Date:  2021-02-08       Impact factor: 4.041

7.  Genomic analysis of 21 patients with corneal neuralgia after refractive surgery.

Authors:  Jun-Hui Yuan; Betsy R Schulman; Philip R Effraim; Dib-Hajj Sulayman; Deborah S Jacobs; Stephen G Waxman
Journal:  Pain Rep       Date:  2020-07-27

8.  Pathogenic Cav3.2 channel mutation in a child with primary generalized epilepsy.

Authors:  Ivana A Souza; Maria A Gandini; Fang-Xiong Zhang; Wendy G Mitchell; Joyce Matsumoto; Jason Lerner; Tyler Mark Pierson; Gerald W Zamponi
Journal:  Mol Brain       Date:  2019-10-24       Impact factor: 4.041

9.  A rare CACNA1H variant associated with amyotrophic lateral sclerosis causes complete loss of Cav3.2 T-type channel activity.

Authors:  Robin N Stringer; Bohumila Jurkovicova-Tarabova; Sun Huang; Omid Haji-Ghassemi; Romane Idoux; Anna Liashenko; Ivana A Souza; Yuriy Rzhepetskyy; Lubica Lacinova; Filip Van Petegem; Gerald W Zamponi; Roger Pamphlett; Norbert Weiss
Journal:  Mol Brain       Date:  2020-03-06       Impact factor: 4.041

10.  Exome Sequencing Implicates Impaired GABA Signaling and Neuronal Ion Transport in Trigeminal Neuralgia.

Authors:  Weilai Dong; Sheng Chih Jin; August Allocco; Xue Zeng; Amar H Sheth; Shreyas Panchagnula; Annie Castonguay; Louis-Étienne Lorenzo; Barira Islam; Geneviève Brindle; Karine Bachand; Jamie Hu; Agata Sularz; Jonathan Gaillard; Jungmin Choi; Ashley Dunbar; Carol Nelson-Williams; Emre Kiziltug; Charuta Gavankar Furey; Sierra Conine; Phan Q Duy; Adam J Kundishora; Erin Loring; Boyang Li; Qiongshi Lu; Geyu Zhou; Wei Liu; Xinyue Li; Michael C Sierant; Shrikant Mane; Christopher Castaldi; Francesc López-Giráldez; James R Knight; Raymond F Sekula; J Marc Simard; Emad N Eskandar; Christopher Gottschalk; Jennifer Moliterno; Murat Günel; Jason L Gerrard; Sulayman Dib-Hajj; Stephen G Waxman; Fred G Barker; Seth L Alper; Mohamed Chahine; Shozeb Haider; Yves De Koninck; Richard P Lifton; Kristopher T Kahle
Journal:  iScience       Date:  2020-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.